Meta-analysis; non-small cell lung cancer; phosphatase and tensin homolog; prognosis. Loss of PTEN expression was associated with poorer overall survival, but had no significant association with disease-free survival. Subgroup analysis showed that negative PTEN expression was associated with a poorer outcome in Asian and ADC patients, but not in Western or squamous cell carcinoma patients. Conclusion: Loss of PTEN might play an unfavorable prognostic role for overall survival of non-small cell lung cancer patients, especially Asian or ADC patients.
Introduction
Lung cancer is the main cause of cancer-related death around the world, with about 1.4 million deaths worldwide each year. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. 1 Although some advances have been achieved in treatments, lung cancer has an extremely poor prognosis, with a five-year overall survival (OS) of 16% in the United States and less than 10% in the United Kingdom. 2 Alone or in combination, the prognostic factors are variable measured indicators of individual patients, which may explain part of the population heterogeneity and provide information on clinical outcomes at the time of diagnosis. The tumor node metastasis (TNM) stage is thought to have an effect on survival in NSCLC patients; however, problems such as similar prognoses for patients with different tumor stages and varied prognoses for patients with the same tumor stage have been indicated. Recent research has revealed that some biological markers may have an impact on survival in NSCLC patients. [3] [4] [5] Phosphatase and tensin homolog (PTEN), also known as mutated in multiple advanced cancer 1 (MMAC1) or TGFβregulated and epithelial cell-enriched phosphatase 1 (TEP1), is a 47 kDa dual specific protein-phospholipid phosphatase, which was first identified as a tumor suppressor gene located at chromosome 10q23.3 by three separate groups of investigators in 1997. [6] [7] [8] PTEN is an important negative regulator of the protein kinase B/phosphatidylinositol 3-kinase (PI3K) pathway, which is one of the most important pathways for cell growth, proliferation, and survival, by dephosphorylating phosphatidylinositol 3,4,5-triphosphate (PIP3) at its D3 position. [9] [10] [11] [12] It has also been suggested that PTEN regulates focal adhesion structure and cell invasion and migration by controlling focal adhesion kinase (FAK) activity. 13, 14 In addition, PTEN can restrict cellular differentiation by decreasing the activation of mitogen-activated protein kinase (MAPK). 15, 16 PTEN may also inhibit angiogenesis by downregulating both hypoxiainducible factor-1 alpha (HIF-1 alpha) and vascular endothelial growth factor (VEGF) in tumor cells. 17, 18 Recently, many studies have indicated that PTEN is related to survival in patients with malignant tumors, including esophageal squamous cell carcinoma, 19 acute myeloid leukemia, 20 and breast, 21 prostate, 22 and gastric cancers. 23 However, the results relating to the prognostic role of PTEN expression in NSCLC are inconsistent among clinical studies; therefore, a systematic review and meta-analysis based on the published literature is necessary to provide further insights into this conflicting issue.
The aim of our study was to identify the prognostic value of PTEN expression in NSCLC patients. We also investigated the correlation between PTEN expression and clinicopathological characteristics.
Methods
This systematic review and meta-analysis was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement protocol. 24 
Search strategy
We searched MEDLINE (via PubMed), Embase (via OVID), CENTRAL (via the Cochrane Library), and the Chinese BioMedical Literature Database (CBM) to October 2016 to identify studies relevant to this review. Our search strategy included the following subject headings and/or keywords variably combined by "lung neoplasm," "PTEN," and "prognosis." The detailed PubMed search strategy is shown in Figure 1 . In addition, reference lists of the articles initially detected were searched manually to identify additional relevant reports. The eligibility of references retrieved by the search was assessed independently by two of the authors, and the review authors resolved differences of opinion by discussion or by appeal to a third review author when necessary. The full text of the remaining articles, including the references, was examined to determine whether the articles contained relevant information.
Inclusion and exclusion criteria
Studies were considered eligible if they met all of the following inclusion criteria: (i) the study population consisted of primary NSCLC patients; (ii) PTEN expression was evaluated in primary lung carcinoma tissues by immunohistochemistry (IHC), reverse-transcriptase (RT)-PCR, or fluorescence in situ hybridization (FISH); and (iii) the association between PTEN expression and OS and disease-free survival (DFS) were measured and/or the associations of PTEN expression and clinical characteristics was reported. Studies were excluded based on any of the following criteria: (i) reviews, letters, laboratory research, and animal experiments were excluded; (ii) the language was not English or Chinese; or (iii) the study lacked critical data for hazard ratio (HR) analysis.
Quality assessment
Quality assessment of individual studies was performed independently by two of the authors, using the NewcastleOttawa Scale (NOS) for cohort studies. The scale allocates stars (maximum of 9) for quality of selection, comparability, and outcome of study participants. 25 NOS scores of >6 were defined as high-quality studies. Any discrepancies were addressed by joint reevaluation of the original article.
Data extraction
Data were extracted from the selected studies independently by two of the authors, using a predefined standardized form and disagreements were resolved by discussion between two review authors or by appealing to a third review author. The original data included PTEN expression, Kaplan-Meier (K-M) survival curves, or HR and 95% confidence interval (CI) of survival outcomes. Multivariate Cox hazard regression analysis data was our priority, but if not obtained, univariate Cox hazard regression analysis or K-M survival curves with log-rank P value of survival outcomes were used instead. Because HRs were not available in all of the included studies, we calculated the HR with 95% CI using survival rates, enrolled samples, and corresponding P values from log-rank test in accordance with the described instructions. The relevant formulas are as follows:
where O − E is the log rank Observed minus Expected events and V is the log rank Variance. 26 We then extracted the associated details by Engauge Digitizer 4.1 (http:// sourceforge.net) from the K-M curves to measure the accuracy of estimated HRs. We extracted basic characteristics, including first author (year), primary treatment, country, study period, study design, number of patients, number of patients with evaluated PTEN expression and/or survival data, stage, method, cut-off/scoring categories, antibody, median follow-up, patients' average age when diagnosed with lung cancer, histology, and attitude conclusion from eligible articles.
Statistical analysis
The log HR was chosen as the appropriate summary statistic because it was the only summary statistic that allowed for both censoring and time to an event. 27 However, these relevant statistical variables were not explicitly provided in most studies; therefore, we extracted associated data from K-M survival curves. We carried out meta-analysis on PTEN expression in NSCLC cells for OS and DFS. We also analyzed correlations between PTEN expression and clinical characteristics, including age, gender, grade, smoking history, histology, primary tumor (pT) stage, TNM stage, lymph node metastasis, and other characteristics. According to clinical characteristics, stages I and II, stages III and IV, T2, T3, and T4 were combined, while welldifferentiated (G1) and moderately differentiated (G2) were combined and poorly differentiated (G3) was separated. Their correlations were described by odds ratio (OR). The effects of PTEN expression on survival outcome (OS/DFS) and correlations between PTEN expression and clinical characteristics were estimated by forest plots. Heterogeneity was defined as P < 0.10 or I 2 > 50%. When homogeneity was good (P > 0.10, I
2 < 50%), a fixed effect model was used to combine effective sizes, otherwise a random effect model was used. Subgroup analyses were performed to investigate the potential causes of heterogeneity according to region, sample size, follow-up period, test methods, and NOS scores. Meta-regression was also used to identify the source of heterogeneity. An observed HR > 1 indicated a worse outcome for the positive group compared with the negative group and was considered significant if the 95% CI did not overlap 1. The potential publication bias was evaluated by Begg's rank correlation and Egger's test, with P > 0.05 indicating no potential publication bias. 28 Meta-analysis and publication biases were both performed by STATA 13.0 (STATA Corporation, College Station, TX, USA).
Results

Reference retrieval
After primary retrieval, a total of 231 potentially relevant studies were initially incorporated into our study, including 121 from MEDLINE, 89 from Embase, 17 from CBM, 1 from CENTRAL, and 3 from reference lists. Forty were excluded as duplicates and 151 were excluded by title/ abstract screening. Full texts were retrieved for the remaining 40 studies. Nineteen retrospective trials finally met all of the criteria for inclusion in the analysis, which included 3071 patients with a median number of 161.6 patients per study (Fig 2) .
Characteristics and qualities of the included studies
The clinical characteristics of the patients are listed in Table 1 . All of the studies were published after 2005. Only one study was a multinational study undertaken in 30 different countries, while the other 18 studies were single-center studies (14 in Asian countries and 4 in Western countries). 39 NSCLC trials included either all histological subtypes [29] [30] [31] [32] [33] [35] [36] [37] [38] [39] [40] [41] [43] [44] [45] [46] [47] (n = 17), or adenocarcinoma (ADC) (n = 2). 34, 42 Data related to local advanced disease (stages I-III) comprised three of the 19 NSCLC trials, 32, 36, 42 while Shin et al. assessed local early disease stage (I). 30 O'Byrne et al. only involved patients with stages III-IV disease and the patients were separated into to two groups according to different treatments (chemotherapy and chemotherapy + cetuximab). 39 In Lim et al.'s study, patients were divided into two groups on the basis of different stage and treatment (stage I treated with surgery and stage IV treated with gefitinib). 45 Quality assessments of individual studies are shown in Table S1 . We used the NOS for cohort studies to assess included studies, which included three aspects (selection, comparability, and outcome) and eight items. All studies scored either six or seven.
Correlation between phosphatase and tensin homolog (PTEN) expression and clinicopathological characteristics
The studies that referred to a correlation between PTEN expression and clinical characteristics were gathered to evaluate the combined ORs. We found that PTEN Table 2) .
Correlation between PTEN expression and survival outcomes
All articles, including 2486 patients, listed the relationship between PTEN expression and survival outcome in NSCLC. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] The combined HR was 0.51 (95% CI 0.42-0.62; P = 0.000, I 2 = 59.5%) for OS in 16 studies (Fig 3) , [29] [30] [31] [32] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] but was 0.82 (95% CI 0.26-2.60; P = 0.733, I 2 = 84.7%) for DFS in three studies (Fig 4; Table 3 ). [33] [34] [35] Negative PTEN expression was a predictor of poor OS (but not DFS) in NSCLC patients. We also conducted subgroup analysis according to region, sample size, follow-up period, test methods, and NOS scores (Table 4) . Interestingly, we found that the patients with positive PTEN tended to have favorable OS in Asian countries (HR 0.46, 95% CI 0.40-0.53; P = 0.027) compared with Western countries (HR 0.82, 95% CI 0.52-1.30; P = 0.319). Four trials for ADC and three for SCC were assessable for OS (Fig 3,  Table 3 ). The combined HR for OS in ADC (95% CI) was 0.61 (0.44, 0.85; I 2 = 0.0%, P = 0.003); however, the combined HR for OS in SCC (95% CI) was 0.78 (0.54, 1.12; I 2 = 40.7%, P = 0.178). Moderate heterogeneity was found in the meta-analysis for HR (OS) of the prognostic role of PTEN expression. Univariable meta-regression was used to identify the source of heterogeneity, and we found that different regions (Asian vs. Western countries) could explain 53.1% of the heterogeneity (P = 0.039), which is consistent with the earlier result in OS subgroup analysis. However, published year (P = 0.942), NOS score (P = 0.506), and TNM stage (P = 0.388) could not explain the heterogeneity.
Assessment of publication bias
Publication bias is a major concern for all forms of metaanalyses, because positive results tend to be accepted by journals while negative results are often rejected or are not even submitted. Two methods, including Begg's funnel plot and Egger's test, were used to evaluate publication bias of the meta-analysis. No publication bias of the prognostic value of PTEN for OS in NSCLC was discovered (Fig 5) . Both the Begg's test (P = 0.112) and the Egger's test (P = 0.272) found little publication bias. Although little publication bias was detected in our study, we caution the poor sensitivity of Begg's and Egger's tests when the number of eligible articles is fewer than 20.
Discussion
Phosphatase and tensin homolog, regarded as a tumor suppressor gene, regulates many cellular processes, including proliferation, survival, energy metabolism, cellular architecture, and motility. 48 PTEN inactivation is frequently found in many tumors, including lung, endometrial, bladder, renal, and breast cancers. 49 We found that PTEN expression was markedly lower in patients with certain clinicopathological characteristics, including men, SCC (vs. ADC), late N status (N1-N3), distant metastasis, and late TNM stage (stage III-IV), which implied that a loss of PTEN expression tended occur in late NSCLC stage and indicated a poor prognosis. No association was found between PTEN expression and age, grade, or primary tumor stage. In the present meta-analysis, we combined 19 published studies including 2486 patients with NSCLC to yield summary statistics, which indicate that negative expression of PTEN has a significant correlation with poorer OS in NSCLC; however, it is not an unfavorable prognostic factor for DFS in NSCLC patients. In subgroup analysis, we found that loss of PTEN expression only predicted adverse clinical outcomes in ADC patients. Interestingly, when we investigated survival by different regions, the poorer OS associated with PTEN loss was only observed in Asian patients. Thus, our results suggest that loss of PTEN expression was a more appropriate prognostic marker for ADC or Asian patients than for SCC or Western patients. However, further studies are required to address this issue. Our study has several limitations. First, the findings of a meta-analysis depend on the quality of the individual studies, as their potential problems and biases may affect the pooled data. According to the NOS quality assessment performed, 10 of the 16 involved studies scored six, and the other six scored seven, which indicated moderate quality of all of the studies. Second, the method of HR extrapolation is potentially biased. If the authors did not report the required statistics, we calculated them from the data available in the article; if this was not possible, we extrapolated them from the survival curves; therefore some subjective data may affect the final conclusion. Third, we did not search unpublished and grey literature databases, which may lead to potential publication bias. Furthermore, there is also a language bias, as we only screened English and Chinese literature.
In conclusion, this meta-analysis implied that a loss of PTEN expression, which is associated with gender, smoking history, histology, TNM stage, N status, and distant metastasis, might play an unfavorable prognostic role for overall survival in NSCLC patients, especially Asian or ADC patients. However, there is moderate heterogeneity between the studies and further rigorous and high-quality investigation of the effectiveness of PTEN as a therapeutic target for NSCLC is warranted. 
